Search
Get in touch!
Linkedin X-twitter Envelope

Bridgewater: The Drivers of US Exceptionalism

In their recent article, the team at Bridgewater analyzes the exceptional performance of US equities over the past decade, breaking down the key drivers of outperformance and discussing the outlook for continued success.

They examine the extraordinary outperformance of US equities over the past decade, with the S&P 500 delivering returns of over 600% since 2010 and significantly outpacing other developed markets. It attributes this success to three main factors: faster revenue growth, bigger margin expansion, and rising P/E multiples.

Here are the key takeaways:

  • US equity outperformance drivers: The exceptional returns of US equities were driven by a combination of faster revenue growth, larger margin expansion, and rising P/E multiples, with each factor contributing roughly equally.
  • Role of US companies and policy: US companies demonstrated superior efficiency, innovation, and capital deployment compared to global peers. This was supported by a favorable pro-corporate environment, including tax cuts and fiscal policies that boosted corporate profits.
  • Technology sector impact: While US outperformance was broad-based, the technology sector played an outsized role, accounting for more than half of the total outperformance. The growing weight of tech in the S&P 500 (from 20% to 40%) significantly impacted overall index performance.
  • Higher expectations priced in: The strong performance has led to higher expectations being priced into US equities, setting a higher bar for future outperformance. US companies now need about 7% EPS growth to generate a normal risk premium, compared to 3% for other developed markets.
  • Future outlook: Continued US outperformance faces challenges as many past drivers (e.g., globalization, tax cuts) may not persist. Future success heavily depends on the technology sector’s ability to deliver, particularly through AI-driven productivity gains across various sectors.

And while the US continues to have significantly better companies, that’s also a lot more priced-in today versus a decade ago.

Click here to go to the external source.

Share the news

Disclaimer of liability

The above has been prepared by Børsgade ApS for information purposes and cannot be regarded as a solicitation or recommendation to buy or sell any security. Nor can the information etc. be regarded as recommendations or advice of a legal, accounting or tax nature. Børsgade cannot be held liable for losses caused by customers’/users’ actions – or lack thereof – based on the information in the above. We have made every effort to ensure that the information in the above is complete and accurate, but cannot guarantee this and accept no liability for errors or omissions.

Readers are advised that investing may involve a risk of loss that cannot be determined in advance, and that past performance and price development cannot be used as a reliable indicator of future performance and price development. For further information please contact info@borsgade.dk

You might also find this interesting:

Michael Mauboussin: Drawdowns Are The Unavoidable Cost of Long-Term Investing

June 6, 2025

Michael Mauboussin from Morgan Stanley Investment Management have published a comprehensive analysis examining stock market drawdowns and recovery patterns from 1985 to 2024. The research reveals that even the most successful investments experience severe price declines, with the median stock suffering an 85% drawdown that takes 2.5 years from peak to trough.

The study analyzed over 6,500 companies and found that more than half never recover to their previous highs. Michael’s work demonstrates that large drawdowns are an inevitable feature of equity investing, affecting individual stocks, mutual funds, and even portfolios with perfect foresight.

Thomas Gayner: My Current Take on Novo Nordisk

June 6, 2025

In his interview, Tom Gayner, CEO of Markel Group, reflects on investment principles shaped by Warren Buffett and Charlie Munger, and offers a detailed assessment of Novo Nordisk. Gayner praises Novo Nordisk for its business quality, global leadership in diabetes treatment, and strong growth trajectory. He credits the company’s disciplined management and innovation in pharmaceuticals as exemplary, aligning with his own standards of long-term value creation.

Michael Mauboussin: Put Expected Value In Your Valuation Toolkit

May 21, 2025

In this article, Michael Mauboussin explores how investors can generate excess returns by focusing on the gap between price and value, emphasizing the practicalities and psychology of expected value in investment decisions. He explains that while price is observable, value is inherently probabilistic, requiring careful estimation of possible payoffs and their probabilities.

The paper covers the challenges of modeling uncertainty, the importance of considering both probabilities and payoffs, the psychological hurdles investors face (like loss aversion), and best practices for applying these concepts across asset classes.

Bill Ackman: Success is Not A Straight Line Up

May 21, 2025

In the 2025 UBS Berkshire Hathaway Fireside Chat, Bill Ackman and Ryan Israel from Pershing Square Capital discuss investment philosophy, market volatility, the impact of tariffs and geopolitics, and lessons from Warren Buffett.

The conversation covers how to identify durable, high-quality businesses, the importance of long-term thinking, and the evolving landscape for activist investing. Ackman shares personal reflections on resilience, mentorship, and the role of free speech, while both speakers provide practical advice for young investors and fund managers.